FLT4 and neoplasm: In other words, binding of tumor-derived VEGF-D to α9 integrin receptor on cancer cells leaves its VEGF-R3 binding site unoccupied, so that the same VEGF-D molecule can also bind to VEGF-R3 expressed by HMVEC-dLy cells to mediate the lymphangiogenic stimulus.